text: Conflict of interest statement 
  
  D.L.B. has acted as a consultant in the last 2 years for AditumBio, 
  Biogen, Biointervene, Combigene, LatigoBio, GSK, Ionis, Lexicon 
  therapeutics, Neuvati, Olipass, Orion, Replay, SC Health Manag- 
  ers, Theranexus, Third Rock Ventures, and Vida Ventures on behalf 
  of Oxford University Innovation. D.L.B. has received research 
  funding from Lilly and Astra Zeneca, and G.A.W. has received 
  research funding from Ono Pharmaceutical. D.L.B. has received 